Biovie (BIVI) Income towards Parent Company (2013 - 2026)
Biovie (BIVI) posted Income towards Parent Company of -$5.3 million for Q1 2026, up 13.17% sequentially from -$6.1 million in Q4 2025, and down 89.01% YoY from -$47.9 million in Q1 2025.
Biovie (BIVI) Income towards Parent Company (2013 - 2026) Analysis & Trends
Biovie has reported Income towards Parent Company for 12 years, with the latest figure at -$5.3 million in Q1 2026.
- Quarterly Income towards Parent Company fell 89.01% year-over-year to -$5.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$20.0 million (down 3.08% YoY) and the FY2025 annual result came in at -$17.9 million, up 45.73% from the prior year.
- Income towards Parent Company climbed to -$5.3 million in Q1 2026 per BIVI's latest filing, from -$6.1 million in the prior quarter.
- Over five years, Income towards Parent Company peaked at -$2.8 million in Q1 2025 and troughed at -$15.7 million in Q4 2022.
- A 5-year average of -$7.8 million and a median of -$7.2 million in 2024 frame the typical range for Income towards Parent Company.
- The widest YoY moves for Income towards Parent Company: up 93.85% in 2022, down 189.73% in 2022.
- Over 5 years, Income towards Parent Company stood at -$15.7 million in 2022, then soared by 46.44% to -$8.4 million in 2023, then grew by 14.81% to -$7.2 million in 2024, then climbed by 15.19% to -$6.1 million in 2025, then gained by 13.17% to -$5.3 million in 2026.
- According to Business Quant data, Income towards Parent Company over the past three periods registered -$5.3 million, -$6.1 million, and -$5.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Biovie | 14.17 Mn | 14.17 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -5.65 Mn |
| Mar 31, 2026 | -5.27 Mn |
| Dec 31, 2025 | -6.07 Mn |
| Sep 30, 2025 | -5.13 Mn |
| Jun 30, 2025 | -3.49 Mn |
| Mar 31, 2025 | -2.79 Mn |
| Dec 31, 2024 | -7.16 Mn |
| Sep 30, 2024 | -4.48 Mn |
| Jun 30, 2024 | -4.94 Mn |
| Mar 31, 2024 | -8.95 Mn |
| Dec 31, 2023 | -8.40 Mn |
| Sep 30, 2023 | -10.71 Mn |
| Jun 30, 2023 | -9.11 Mn |
| Mar 31, 2023 | -15.04 Mn |
| Dec 31, 2022 | -15.69 Mn |
| Sep 30, 2022 | -10.42 Mn |
| Jun 30, 2022 | -8.09 Mn |
| Mar 31, 2022 | -7.04 Mn |
| Dec 31, 2021 | -5.41 Mn |
| Sep 30, 2021 | -5.54 Mn |